$ACOG

Opaleye Management Inc. purchased $59K of ACOG (indirect holdings)

Opaleye Management Inc. purchased 10,054 indirectly-held shares of Alpha Cognition Inc. (ACOG) at $5.83 on 2026-06-05.

Original reporting
SEC EDGAR · Opaleye Management Inc.
Published Jun 9, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 9, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ACOG
Bullish
medium confidence
Mentioned
$ACOG
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACOGBullishLow
01

Why it matters

Traders may treat the disclosure as a minor positive sentiment datapoint, but it does not provide new operational or financial fundamentals.

02

Market read

New insider accumulation fact disclosed via SEC EDGAR; likely low incremental trading impact absent follow-on activity.

03

What to watch

No 10b5-1 plan is cited; without context on prior trading cadence or total ownership changes, the signal strength is uncertain.

Relevance 4/10Novelty 8/10Timing: Form 4 filed June 9 (transaction dated June 5)

Background

The filing is an SEC Form 4 insider transaction: Opaleye Management Inc. reported an open-market purchase in Alpha Cognition Inc. stock.

Company-level read

Ticker impact

$ACOGBullishMedium confidence
Context

Opaleye Management Inc. (a 10% owner) bought 10,054 shares of Alpha Cognition Inc. for ~$58.6K via an open-market Form 4 filed June 9.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and should fade unless followed by larger buys or fundamental catalysts.

Evidence & confidence

The article is a primary SEC Form 4 disclosure (new fact), but the transaction size (~$59K) is relatively small, and there is no 10b5-1 plan disclosed.

Market effects

No sector-level implications; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

A small open-market buy by a 10% owner may reflect routine portfolio management rather than a strong forward-looking view.

Key entities

  • Alpha Cognition Inc.

    Subject of the Form 4 insider transaction; shares purchased by a 10% owner.

  • Opaleye Management Inc.

    10% owner reporting an open-market purchase of ACOG shares.

Related articles

$ACOGMed

Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease

Alpha Cognition Inc. (NASDAQ: ACOG) said the European Patent Office granted a European patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in treating mild-to-moderate Alzheimer’s disease. The patent covers specific solid form, compositions, manufacturing and medical-use claims, with potential protection into 2042, subject to requirements.